# Virological and serological characterization of critically ill patients with COVID-19 in the UK: a special focus on variant detection

Jeremy Ratcliff BSc<sup>1</sup>, Dung Nguyen PhD<sup>1</sup>, Matthew Fish<sup>2</sup>, Jennifer Rhynne<sup>2</sup>, Aislinn Jennings<sup>2</sup>, Sarah Williams BMBCh<sup>1</sup>, Farah Al-Beidh PhD<sup>3</sup>, David Bonsall MD, PhD<sup>4,5</sup>, Amy Evans<sup>6</sup>, Tanya Golubchik PhD<sup>5</sup>, Anthony C Gordon MBBS, MD<sup>3,7</sup>, Abigail Lamikanra PhD<sup>8</sup>, Pat Tsang MSc<sup>8</sup>, Nick Ciccone PhD<sup>8</sup>, Ullrich Leuscher BSc<sup>8</sup>, Wendy Slack<sup>8</sup>, Emma Laing<sup>6</sup>, Paul R Mouncey MSc<sup>9</sup>, Sheba Ziyenge MSc<sup>8,10</sup>, Marta Olivera BSc<sup>10, 11</sup>, Rutger Ploeg PhD<sup>10,11</sup>, Kathryn M Rowan PhD<sup>9</sup>, Manu Shankar-Hari MD, PhD<sup>2,12</sup>, David J. Roberts FRCPath, D.Phil<sup>8,13</sup>, David K Menon MD, PhD<sup>14</sup>, Lise Estcourt MBBCh, PhD<sup>6,13</sup>, Peter Simmonds MD, PhD<sup>1#</sup> & Heli Harvala MD, PhD<sup>15</sup>\*\*

on behalf of the REMAP-CAP Immunoglobulin Domain UK Investigators (listed in the Supp. Appendix).

\*To whom correspondence should be addressed.

Tel. +44 7747 096974

Email: Heli.HarvalaSimmonds@nhsbt.nhs.uk

Key words: SARS-CoV-2 COVID-19 Coronavirus Polymerase Chain Reaction

Diagnostics Variant of Concern Clade B.1.1.7

Abstract: 297 words

Main text: 3171 words

<sup>&</sup>lt;sup>1</sup>Nuffield Department of Medicine, Peter Medawar Building for Pathogen Research, University of Oxford, UK;

<sup>&</sup>lt;sup>2</sup>School of Immunology & Microbial Sciences, Kings College London, UK;

<sup>&</sup>lt;sup>3</sup>Imperial College London, London, UK;

<sup>&</sup>lt;sup>4</sup>Big Data Institute, Li Ka Shing Centre for Health Information and Discovery, Nuffield Department of Medicine, University of Oxford, Oxford, UK;

<sup>&</sup>lt;sup>5</sup>Wellcome Centre for Human Genetics, University of Oxford, Oxford, UK;

<sup>&</sup>lt;sup>6</sup>Clinical Trials Unit, NHS Blood and Transplant, Oxford, UK;

<sup>&</sup>lt;sup>7</sup>Imperial College Healthcare NHS Trust, St. Mary's Hospital, London, UK;

<sup>&</sup>lt;sup>8</sup>Clinical, Research and Development, NHS Blood and Transplant, Oxford, UK;

<sup>&</sup>lt;sup>9</sup>Intensive Care National Audit & Research Centre (ICNARC), London, UK;

<sup>&</sup>lt;sup>10</sup>Nuffield Department of Surgical Sciences and BRC Surgical Theme, University of Oxford, UK;

<sup>&</sup>lt;sup>11</sup>NHS Blood and Transplant Research Laboratory, Oxford, UK;

<sup>&</sup>lt;sup>12</sup>Guy's and St Thomas' NHS Foundation Trust, St Thomas' Hospital, London, UK;

<sup>&</sup>lt;sup>13</sup>Radcliffe Department of Medicine and BRC Haematology Theme, University of Oxford, John Radcliffe Hospital, Oxford, UK;

<sup>&</sup>lt;sup>14</sup>University Division of Anaesthesia, University of Cambridge, Addenbrooke's Hospital Cambridge, Cambridge, UK;

<sup>&</sup>lt;sup>15</sup>Microbiology Services, NHS Blood and Transplant, London, UK.

<sup>#</sup> shared last authors

**ABSTRACT** 

2

**Background.** Treatment of COVID-19 patients with convalescent plasma containing neutralising antibody to SARS-CoV-2 is under investigation as a means of reducing viral loads, ameliorating disease outcomes, and reducing mortality. However, its efficacy might be reduced in those infected with the emerging B.1.1.7 SARS-CoV-2 variant. Here, we report the diverse virological characteristics of UK patients enrolled in the Immunoglobulin Domain of the REMAP-CAP randomised controlled trial.

**Methods.** SARS-CoV-2 viral RNA was detected and quantified by real-time PCR in nasopharyngeal swabs obtained from study subjects within 48 hours of admission to intensive care unit. Antibody status was determined by spike-protein ELISA. B.1.1.7 strain was differentiated from other SARS-CoV-2 strains by two novel typing methods detecting the B.1.1.7-associated D1118H mutation with allele-specific probes and by restriction site polymorphism (*Sfc*I).

**Findings.** Of 1260 subjects, 90% were PCR-positive with viral loads in nasopharyngeal swabs ranging from 72 international units [IUs]/ml to  $1.7 \times 10^{11}$  IU/ml. Median viral loads were 45-fold higher in those who were seronegative for IgG antibodies (n=314; 28%) compared to seropositives (n=804; 72%), reflecting in part the latter group's possible later disease stage on enrolment. Frequencies of B.1.1.7 infection increased from early November (<1%) to December 2020 (>60%). Anti-SARS-CoV-2 seronegative individuals infected with wild-type SARS-CoV-2 had significantly higher viral loads than seropositives (medians of  $1.2 \times 10^6$  and  $3.4 \times 10^4$  IU/ml respectively;  $p=2 \times 10^{-9}$ ). However, viral load distributions were elevated in both seropositive and seronegative subjects infected with B.1.1.7 (13.4x10<sup>6</sup> and 7.6x10<sup>6</sup> IU/ml; p=0.18).

**Interpretation.** High viral loads in seropositive B.1.1.7-infected subjects are consistent with increased replication capacity and/or less effective clearance by innate or adaptive immune response of B.1.1.7 strain than wild-type. As viral genotype was associated with diverse virological and immunological phenotypes, metrics of viral load, antibody status and infecting strain should be used to define subgroups for analysis of treatment efficacy.

## INTRODUCTION

The catastrophic zoonotic emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the human population in China at the end of 2019, and its subsequent pandemic spread has caused global devastation. By the end of January 2021, over 100 million infections and over 2 million COVID-19-associated deaths have been reported worldwide To date, only limited treatment regimens exist for COVID-19 patients<sup>1,2</sup>, and their management is primarily supportive, with case-fatality rates remaining at 1% - 2% in Western countries including the UK<sup>3</sup>. In the search of alternative methods to treat COVID-19, convalescent plasma therapy boosting levels of neutralising antibody has been considered as a potential means to reduce morbidity and mortality<sup>4,5</sup>, particularly if given in early stages of infection<sup>6</sup>. RECOVERY and REMAP-CAP are randomized controlled trials investigating the efficacy of convalescent plasma therapy conducted in the UK with REMAP-CAP also recruiting participants globally<sup>6,7</sup>. In the REMAP-CAP trial<sup>7</sup> patients with severe COVID-19, restricted to those in intensive care units (ICUs), are transfused with one to two plasma units collected from donors with previous documented SARS-CoV-2 infection and confirmed to have high plasma titres of neutralising antibody (>1:100 based on *in vitro* live virus neutralisation assays) using surrogate testing with a spike antigen-based ELISA<sup>8</sup>.

While final statistical analysis is awaited, both trials have been paused as an initial analysis did not show a significant benefit of treatment across the overall study population in terms of either COVID-19 associated mortality or number of organ-support free days<sup>9,10</sup>. However, analysis of the data will need to account for patient variables that may influence treatment efficacy, and address patient outcomes other than death. For example, the potential efficacy of convalescent plasma therapy may be influenced by disease stage at trial enrolment. Severe COVID-19 disease may be driven by either the direct effects of virus replication in the respiratory tract, or secondarily from damage associated with the often intense inflammatory antiviral response that usually leads to clearance of SARS-CoV-2. Treatment with neutralising antibody may primarily influence outcomes during the early stages of active virus replication-induced disease but could be less relevant in those patients who have cleared their infection and seroconverted for anti-SARS-CoV-2 antibody. Therefore, we have determined the pre-treatment viral loads in respiratory samples and serological status to categorise study subjects by their disease stage.

Another variable influencing treatment outcomes may originate from effects of strain variation of SARS-CoV-2. A variant of SARS-CoV-2 with a D614G mutation in the spike protein has been described <sup>11,12</sup> along with more recent mutants such as B.1.1.7 in the UK, B.1.351 in South Africa and B.1.1.28 in Brazil <sup>13</sup>, all potentially more transmissible <sup>14</sup>; furthermore, B.1.1.7 may result in a higher mortality than the original pandemic strain <sup>15</sup>. As regards B.1.351 (South Africa), clustered amino acid changes in the spike protein gene may render this mutant partially antigenically distinct from the prototype strain <sup>16</sup>. These virological differences, including the possibility of antigenic escape from neutralising antibodies in convalescent plasma collected from individuals with earlier strains of SARS-CoV-2, may individually or collectively affect the efficacy of convalescent plasma therapy. To identify SARS-CoV-2 strains, we developed a real-time PCR targeting the D1118H polymorphism in the spike gene that is characteristic of the B.1.1.7 strain. This provided a rapid means to differentiate B.1.1.7 from other SARS-CoV-2 strains; in addition, the assay was found to be more effective than high throughput sequencing for low viral load samples. A simpler agarose gel-based method was also developed and evaluated to enable B.1.1.7 identification in resource-limited settings.

Using these methods, we report substantial variability in pre-treatment viral loads, variability in serological status and an increasing detection of B.1.1.7 during the enrolment period of UK participants in the international REMAP-CAP trial<sup>7</sup>. Measurement of these variables will be of considerable value in analysing effects of convalescent plasma therapy and potentially identifying sub-groups of patients for whom this treatment may be effective.

### **MATERIALS AND METHODS**

4

Patient Recruitment and Sample Collection. All subjects were enrolled in the UK and had a laboratory confirmed diagnosis of SARS-CoV-2 infection with concomitant severe pneumonia requiring ICU admission. Patients were not eligible if more than 48 hours had elapsed since their ICU admission, if they had already received treatment with any other non-trial prescribed antibody therapy (monoclonal antibody, hyperimmune immunoglobulin, or convalescent plasma) or if more than 14 days had elapsed since hospital admission. A total of 122 hospitals have recruited patients in this trial in the UK (Table S1; Suppl. Data)<sup>17</sup>. Nasopharyngeal or oropharyngeal swabs and serum samples for baseline virological testing were collected from patients prior to the enrolment and frozen at -80°C.

**Ethical statement.** The study was conducted according to the principles of the latest version of the Declaration of Helsinki (version Fortaleza 2013), and in accordance with regulatory and legal requirements (EudraCT number: 2015-002340-14). The study was approved by London-Surrey Borders Research Ethics Committee London Centre (18/LO/0660). Written or verbal informed consent, in accordance with regional legislation, is obtained from all patients or their surrogates.

Nucleic Acid Extraction. Viral RNA was extracted from patient samples using the QIAamp Viral RNA Mini Kit (QIAGEN). 140  $\mu$ L of respiratory sample was mixed with 560  $\mu$ L of Buffer AVL containing 20  $\mu$ g/mL of linear polyacrylamide (ThermoFisher Scientific), extracted according to the manufacturer's spin protocol, and eluted into 60  $\mu$ L of buffer AVE. Samples that arrived dry were resuspended in 2 mL of PBS and incubated at room temperature for 20 minutes prior to extraction. NIBSC research reagent 19/304 (https://nibsc.org/products/brm\_product\_catalogue/detail\_page.aspx?catid=20/146) was extracted using the QIAamp Viral RNA Mini Kit and serially diluted in RNA storage solution (Thermo Fisher Scientific; 1 $\mathbb{Z}$ mM sodium citrate, pH 6.4) containing herring sperm carrier RNA (50 $\mathbb{Z}$  $\mu$ g/mL) and RNasin (New England BioLabs UK, 100 $\mathbb{Z}$ U/mL). All samples were subject to a single freeze-thaw cycle between extraction and RT-PCR quantification.

Real-time Polymerase Chain Reaction (PCR). Viral RNA was detected and quantified by real-time polymerase chain reaction (RT-PCR) using the Quantitect Probe RT-PCR kit (QIAGEN) with CDC N1 primers (Table 1; <a href="https://www.cdc.gov/coronavirus/2019-ncov/lab/rt-pcr-panel-primer-probes.html">https://www.cdc.gov/coronavirus/2019-ncov/lab/rt-pcr-panel-primer-probes.html</a>) (final concentrations 500 nM for primers and 125 nM for probe (ATDBio)) in 20 μL reaction volumes and 5 μL of extracted RNA. RT-PCR was carried out on an Applied Biosystems StepOnePlus Real-Time PCR system (ThermoFisher Scientific) with the following settings: 50°C for 30m, 95°C for 15m, and 40 cycles of 94°C for 15s and 60°C for 1m. Intra-assay variation was standardized through use of a standard curve of NIBSC RNA control 19/304 serially diluted from 10,000 copies/reaction to 100 copies/reaction. RT-PCR Ct values were converted to copy number/reaction by use of the standard curve and to international units/mL by the conversion rate provided by NIBSC.

Typing assays to identify B.1.1.7 SARS-CoV-2 strains. An RT-PCR using allele-specific probes (ASP) and nested PCR Restriction Fragment Length Polymorphism for the  $G \rightarrow C$  polymorphism at position 24814 (D1118H) (Table S1; Suppl. Data) were used to differentiate wild-type and B.1.1.7 strains. Detailed methods are available as Protocols A and B (Suppl. Data).

5

Nucleotide sequencing. Whole virus genomes were sequenced using the virus-specific PCR-free

sequencing method veSEQ. The full method description is provided in Protocol C (Suppl. Data).

Serology. Baseline blood samples were also collected from all patients to determine the presence of

SARS-CoV-2 IgG antibodies against spike protein at the time of transfusion. These were determined

using the recently developed and validated 386-well plate ELISA coupled with an automated liquid

handler<sup>18</sup>.

**RESULTS** 

6

Trial enrolment. Viral loads and anti-SARS-CoV-2 IgG antibody status were determined in respiratory

and/or serum samples collected from patients enrolled into REMAP-CAP trial in the UK from 25<sup>th</sup> May

2020 through 4<sup>th</sup> January 2021.

Pre-treatment viral loads. RNA extracted from respiratory samples was amplified by real-time PCR using

CDC N1 (nucleoprotein gene) primers (Fig. 1A). Ct values were converted to viral loads through co-

amplification and calibration with the SARS-CoV-2 international reference standard (NIBSC, UK). This

placed the assay sensitivity threshold at 100 copies/ml for samples with Ct values >35. Using this

calibrated assay, a total of 1129 from 1260 samples (89%) were SARS-CoV-2 RNA positive. Viral loads

ranged from <100 IU/ml to 1.7 x 10<sup>11</sup> IU/ml, a remarkable >2 billion-fold range in levels of secreted virus.

Serology. The serological status of each enrolled patient was determined by ELISA to recombinant spike

protein. Results were expressed as positive and negative although the degree of antibody reactivity

could not be quantified by the nature of the assay. Antibody status has been determined in 1118

patients included in this study to date, of whom 804 were determined as seropositive (72%). The

median viral load of seronegative individuals was 36x higher than seropositives with markedly different

distributions of viral loads between the two groups (Fig. 1A). The proportion of seropositive patients

varied systematically with viral load ranges, being highest (85%) in those with the lowest viral load (<

through to 48% in those with viral loads >108 IU/ml (Fig. 1B).

**SARS-CoV-2 strain identification**. As infections with the emerging B.1.1.7 strain may respond differently

to treatment compared to previously circulating strains of SARS-CoV-2, two different typing assays were

developed to identify B.1.1.7 in trial patients. We first analysed the specificity and predictive value of individual polymorphic sites in the spike gene of B.1.1.7 (H69/V70del., Y144del., N501Y, A570D, P681H, T716l, S982A, D1118H) that differentiated them from other SARS-CoV-2 strains (Table 1). All but one of the defined polymorphisms differentiated B.1.1.7 with very high sensitivity and specificity from previously circulating strains in the UK and from emerging strains in South Africa and Brazil (B.1.351 and B.1.1.28). The exception was the H69/V70 del site which showed increasing frequencies with time in multiple lineages of wild-type strains (Table S2; Suppl. Data). As the G->C change associated with D1118H also led to the loss of a restriction enzyme site (*Sfc*I), amplicons from this region were used in typing assays with allele-specific probes (ASP; Fig. S1A; Suppl. Data) and nested-PCR RFLP assays (Fig. S1B; Suppl. data).

For baseline genomic characterisation, the first 284 respiratory samples collected in November 2020 from the trial patents were sequenced by HTS using SARS-CoV-2-baited target enrichment. Variable coverage of the genome was achieved, associated with viral load (Fig. S2; Suppl. Data). All sequences with coverage over codon 164 of the spike gene showed the D614G mutation. Phylogenetic analysis (Fig. S3; Suppl. Data) of those samples showing >65% sequence coverage demonstrated that the majority fell into the lineage GV (according to its designation in GISAID). Of the sequences obtained, 13 of the 173 sequences with sufficient sequence in the spike gene to enable assignment were identifiable as B.1.1.7. No sequences corresponded to emerging strains B.1.351 (South Africa) or B.1.1.28 (Brazil).

A subset of 40 samples sequenced across the spike gene were used for evaluation of the typing assays. These produced highly concordant results with 100% specificity, 97.5% sensitivity for the ASP assay, and 97.5% specificity, 93.5% sensitivity for the RFLP assay (Table S3; Suppl. Data). Study samples were typed by a combination of the three methods with 521 (400 WT; 121 B.1.1.7) from 645 from tested (81%) successfully typed.

Emergence and virological associations of SARS-CoV-2 strains. Infections with the B.1.1.7 strain were first detected among enrolled patients in early November and rapidly increased in frequency through November and December, representing over two thirds of infections in the week beginning 21<sup>st</sup> December 2020 (Fig. 2). Frequencies of B.1.1.7 infections matched their emergence in the general UK population based on analysis of SARS-CoV-2 sequences deposited on GISAID in the corresponding study weeks, albeit at a 1.5-2-fold consistently greater frequency. Geographically, B.1.1.7 infections occurred

7

at greatest frequency in subjects enrolled in South East England (including London) and in East England (approximately 50%; Fig. 3). Cohort enrolment from different regions of England closely matched the proportions of COVID-19 diagnoses reported to PHE over the study period.

Viral loads ranges from subjects infected with the B.1.1.7 strain differed substantially from those with wild-type SARS-CoV-2, with medians of 10,146,774 and 820,689 IU/ml respectively ( $p=2\times10^{-9}$ ). Remarkably, significant differences in viral loads were only apparent among subjects who were seropositive for SARS-CoV-2 antibody (Fig. 4), with an approximately 40-fold difference between medians of B.1.1.7 and wild-type infections. Contrastingly, viral loads varied by less than 2-fold between those with B.1.1.7 and wild-type infections in seronegative subjects. Seropositivity had no significant effect on B.1.1.7 viral loads (p=0.47). Viral load distributions were elevated in both seropositive and seronegative subjects infected with B.1.1.7 (13.4x10<sup>6</sup> and 7.6x10<sup>6</sup> IU/ml; p=0.18).

**DISCUSSION** 

8

This is the first study to demonstrate that median viral loads were substantially higher (45-fold) in seronegative COVID-19 patients admitted to the intensive care unit compared to seropositives. This difference was almost entirely due to 40-fold higher median viral loads in seropositive B.1.1.7-infected subjects compared to seropositive wild type -infected subjects. These data are consistent with different kinetics of viral growth, removal, and seroconversion in B.1.1.7-infection compared to wild-type SARS-CoV-2 infection. Our findings suggest that sub-group analysis of therapeutic trials for COVID-19 should examine outcomes not only by viral load and the presence or absence of anti-spike antibody, but also according to viral genotype that may influence the observed treatment efficacy of convalescent plasma.

The motivation for this study was the need to measure virological variables that can influence the efficacy of convalescent plasma therapy, including the emerging new SARS-CoV-2 variants with potentially reduced neutralisation capacity<sup>11,16,19</sup> and greater pathogenicity<sup>15,20</sup>. Such analyses have been rarely performed in previous or ongoing COVID-19 treatment trials, yet the findings in this severely unwell patient cohort indicate that the studied patients were virologically highly heterogeneous.

Viral loads were determined using quantitative RT-PCR and results calibrated into international units; the use of the NIBSC international standard to express quantitative data using a common standard allows comparison of viral load data obtained in this and independent studies. As previously mentioned, the often reported Ct values provide only an indirect metric of viral load, differing for example through varying efficiencies of primer/probe combinations<sup>21</sup>, which implies that quantitative results are not directly comparable. Most striking was the observation of an approximately billion-fold variation in SARS-CoV-2 viral loads as evaluated by a sensitive and quantitative real time RT-PCR for the conserved N gene. This range is consistent with previous studies that report transient, high levels of SARS-CoV-2 RNA detection in acute infection in nasopharyngeal samples. However, the predictive value of viral loads for clinical outcomes or treatment response is unclear, with several studies reporting significant<sup>22,23</sup>, minimal<sup>24</sup> or no<sup>25</sup> associations with increased severity or mortality from COVID-19.

The extreme range of viral loads we observed is consistent with the kinetics of SARS-CoV-2 secretion in the respiratory tract, where rapid decline following the acute infection stage were observed <sup>23,25</sup>. Indeed, the observation that RNA levels were <100 IU/ml in 10% of subjects on PCR screening (Fig. 1A) despite severe COVID-19 leading to ICU admission suggests that a substantial element in the disease mechanisms of this latter group is inflammatory or cytokine-related, rather than being directly virally induced. The higher frequency of seropositivity for SARS-CoV-2 in subjects who were classed as PCR-negative or showed lower viral loads in those infected with the virus with the wild-type genotype (Fig. 1B) provides further evidence for differences in the timings of severe disease presentations relative to the evolution of SARS-CoV-2 infection. Viral loads and anti-SARS-CoV-2 antibody status may therefore be additionally determined by the timing of ICU admission relative to disease onset rather than just intrinsic variability in virus replication between individuals in those infected with the virus with the wild-type genotype.

Prospectively, evaluation of disease stage by viral load measurements and serological status provides potentially valuable information for patient stratification in treatment selection for COVID-19. Antiviral effect of neutralising antibodies in convalescent plasma may be most appropriately employed for patients in early disease stages where respiratory tract pathology is primarily virus-driven. Conversely, those presenting late post-seroconversion may therefore not be helped by infusion of additional neutralising antibodies where disease mechanisms may primarily derive from inflammation-mediated damage and who may better respond to interventions that modulate host response (corticosteroids, IL-

6 receptor antagonists<sup>1,26</sup>). The importance of identifying those at early stages of infection is demonstrated by the efficacy of convalescent plasma given within 3 days from disease onset<sup>6</sup> whereas no benefit was seen when plasma was used in later stage infections (median 8 days from onset<sup>27</sup>).

The effects of mutations in the spike gene on the transmissibility, viral loads, disease severity and potential antigenic variation is currently an area of substantial concern for COVID-19 pandemic management, public health measures and immunisation programmes. SARS-CoV-2 strains in clade B.1.1.7 have become increasingly prevalent in the UK population whilst the REMAP-CAP convalescent plasma trial patients were drawn (Fig. 2). The spike mutations may lead to a reduction in susceptibility to neutralisation by antibodies elicited by infection or immunisation with previously circulating variants of SARS-CoV-2<sup>19,28</sup>.

The development of practical methods for rapid and large-scale identification of B.1.1.7 strains is therefore of paramount importance for monitoring its spread worldwide, given its greater propensity to transmit<sup>14</sup> and overcome containment measures put in place for previously circulating strains of SARS-CoV-2. The RFLP assay furthermore enables typing to be done with simple laboratory equipment in resource-limited diagnostic facilities without access to HTS or real-time PCR equipment.

The study subjects showed a substantial representation of B.1.1.7 infections, particularly those recruited towards the end of the study period (Fig. 2), mirroring the appearance of this variant in the wider UK population over this period among primarily non-hospitalised individuals. Very recent investigations have provided evidence that B.1.1.7 infections show a 1.7-fold higher hazard of death within 28 day of diagnosis<sup>20</sup>. These findings are consistent with some, but not all, ongoing studies (summarised in<sup>15</sup>), including higher relative case fatality ratios between B.1.1.7 and WT of 1.29-1.36 (Imperial College London) and mortality hazard ratios of 1.7 (PHE) and 1.7 (University of Exeter). In this context, the finding of substantially higher median viral loads in B.1.1.7 infections compared to wild-type in the REMAP-CAP cohort is of substantial mechanistic relevance. The observation that viral loads were higher in B.1.1.7 only in those who had already seroconverted for anti-SARS-CoV-2 antibody (x40-fold; Fig. 4) are consistent with replication capacity and/or a less effective cellular or humoral host immune response to contain B.1.1.7 replication than wild-type. This contrasts with the G614 spike mutant that manifested greater *in vitro* fitness and replicative capacity compared to wild-type strains with D614<sup>29</sup>. The further variable that may influence the efficacy of convalescent plasma therapy is antigenic

variation; the possibility that B.1.1.7-associated amino acid changes in the spike gene may lead to

greater resistance to neutralisation is supported by observations of reduced neutralisation susceptibility

of B.1.1.7 pseudotypes compared to wild type in some<sup>19</sup> although not all<sup>30</sup> studies.

Virus strain characterisation contributes substantially to the virological characterisation of the REMAP-

CAP cohort and its association with higher viral loads may potently influence treatment response. While

current indications from the REMAP-CAP trial demonstrate no overall effect on the treated cohort

compared to untreated controls<sup>10</sup>, data obtained in the current results will form the basis for further

analyses of subgroups defined by antibody status, viral load band and by infecting strain. While this

analysis is post hoc, findings may identify specific patient groups who will benefit from convalescent

plasma and related immunotherapies in the future.

**ACKNOWLEDGEMENTS** 

Funding: This study was supported by National Institute for Health (UKRIDHSC COVID-19 Rapid

Response Rolling Call, "The use of convalescent plasma to treat hospitalised and critically ill patients

with COVID-19 disease", Grant Reference Number COV19-RECPLAS), the European Commission

(SUPPORT-E #101015756), the Platform for European Preparedness Against (Re-) emerging Epidemics

(PREPARE) consortium, the European Union, FP7-HEALTH-2013-INNOVATION-1 (#602525), the Rapid

European COVID-19 Emergency Research response (RECOVER) consortium by the European Union's

Horizon 2020 research and innovation programme (#101003589), the UK National Institute for Health

Research (NIHR) and the NIHR Imperial Biomedical Research Centre. ACG is funded by an NIHR Research

Professorship (RP-2015-06-18) and MSH by an NIHR Clinician Scientist Fellowship (CS-2016-16-011).

DKM is supported by the NIHR throughout the Cambridge NIHR BRC, and the Addenbrooke's Charitable

Trust.

11

The views expressed in this publication are those of the authors and not necessarily those of the NHS,

the National Institute for Health Research or the Department of Health and Social Care.

Support: We are grateful to the NIHR Clinical Research Network (UK) for their support of participant

recruitment. We are grateful to the UK Blood Services (NHS Blood and Transplant, Northern Ireland

Blood Transfusion Service, Scottish National Blood Transfusion Service and Welsh Blood Service) for the supply of convalescent plasma in the UK.

## **CONFLICTS OF INTEREST**

The authors report no conflicts of interest.

### **REFERENCES**

- 1. Angus DC, Derde L, Al-Beidh F, et al. Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial. *Jama* 2020; **324**(13): 1317-29.
- 2. Wang Y, Zhang D, Du G, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. *Lancet* 2020; **395**(10236): 1569-78.
- 3. Harman K, Allen H, Kall M, Dabrera G. Interpretation of COVID-19 case fatality risk measures in England. *J Epidemiol Community Health* 2021.
- 4. Duan K, Liu B, Li C, et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. *Proc Natl Acad Sci U S A* 2020; **117**(17): 9490-6.
- 5. Shankar-Hari M, Estcourt L, Harvala H, Roberts D, Menon DK. Convalescent plasma to treat critically ill patients with COVID-19: framing the need for randomised clinical trials. *Crit Care* 2020; **24**(1): 449.
- 6. Libster R, Pérez Marc G, Wappner D, et al. Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults. *N Engl J Med* 2021.
- 7. Angus DC, Berry S, Lewis RJ, et al. The REMAP-CAP (Randomized Embedded Multifactorial Adaptive Platform for Community-acquired Pneumonia) Study. Rationale and Design. *Ann Am Thorac Soc* 2020; **17**(7): 879-91.
- 8. Harvala H, Mehew J, Robb ML, et al. Convalescent plasma treatment for SARS-CoV-2 infection: analysis of the first 436 donors in England, 22 April to 12 May 2020. Euro surveillance: bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin 2020; 25(28).
- Statement from the RECOVERY trial chief investigators, 15 January 2021. 2021.
   <a href="https://www.recoverytrial.net/news/statement-from-the-recovery-trial-chief-investigators-15-january-2021-recovery-trial-closes-recruitment-to-convalescent-plasma-treatment-for-patients-hospitalised-with-covid-19.">https://www.recoverytrial.net/news/statement-from-the-recovery-trial-chief-investigators-15-january-2021-recovery-trial-closes-recruitment-to-convalescent-plasma-treatment-for-patients-hospitalised-with-covid-19.</a>
- 10. O'Hare R. Blood plasma treatment has limited effect for sickest COVID-19 patients. 2021. https://www.imperial.ac.uk/news/211493/blood-plasma-treatment-limited-effect-sickest/.
- 11. Plante JA, Liu Y, Liu J, et al. Spike mutation D614G alters SARS-CoV-2 fitness and neutralization susceptibility. *bioRxiv* 2020.
- 12. Volz E, Hill V, McCrone JT, et al. Evaluating the Effects of SARS-CoV-2 Spike Mutation D614G on Transmissibility and Pathogenicity. *Cell* 2021; **184**(1): 64-75.e11.

- 13. Voloch CM, Silva F Rd, de Almeida LGP, et al. Genomic characterization of a novel SARS-CoV-2 lineage from Rio de Janeiro, Brazil. *medRxiv* 2020: 2020.12.23.20248598.
- 14. Volz E, Mishra S, Chand M, et al. Transmission of SARS-CoV-2 Lineage B.1.1.7 in England: Insights from linking epidemiological and genetic data. *medRxiv* 2021: 2020.12.30.20249034.
- 15. NERVTAG\_update\_note\_on\_B.1.1.7\_severity. 2021.
  <a href="https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment\_data/file/961042/S1095">https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment\_data/file/961042/S1095</a> NERVTAG update note on B.1.1.7 severity 20210211.pdf.
- 16. Wibmer CK, Ayres F, Hermanus T, et al. SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma. *bioRxiv* 2021: 2021.01.18.427166.
- 17. UK REMAP-CAP Trial. 2020.
  <a href="https://static1.squarespace.com/static/5cde3c7d9a69340001d79ffe/t/5f5c842bd7bf523730bdda76/1599898680445/REMAP-CAP+COVID-19+Immunoglobulin+Therapy+Domain-Specific+Appendix+V1.01-+01+June+2020.pdf">https://static1.squarespace.com/static/5cde3c7d9a69340001d79ffe/t/5f5c842bd7bf523730bdda76/1599898680445/REMAP-CAP+COVID-19+Immunoglobulin+Therapy+Domain-Specific+Appendix+V1.01-+01+June+2020.pdf
- 18. Performance characteristics of five immunoassays for SARS-CoV-2: a head-to-head benchmark comparison. *The Lancet Infectious diseases* 2020; **20**(12): 1390-400.
- 19. Muik A, Wallisch AK, Sänger B, et al. Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine-elicited human sera. *Science* 2021.
- 20. Davies NG, Jarvis CI, Edmunds WJ, Jewell NP, Diaz-Ordaz K, Keogh RH. Increased hazard of death in community-tested cases of SARS-CoV-2 Variant of Concern 202012/01. *medRxiv* 2021: 2021.02.01.21250959.
- 21. Dahdouh E, Lázaro-Perona F, Romero-Gómez MP, Mingorance J, García-Rodriguez J. C(t) values from SARS-CoV-2 diagnostic PCR assays should not be used as direct estimates of viral load. *The Journal of infection* 2020.
- 22. Zacharioudakis IM, Zervou FN, Prasad PJ, et al. Association of SARS-CoV-2 genomic load trends with clinical status in COVID-19: A retrospective analysis from an academic hospital center in New York City. *Plos One* 2020; **15**(11): e0242399.
- 23. Lui G, Ling L, Lai CK, et al. Viral dynamics of SARS-CoV-2 across a spectrum of disease severity in COVID-19. *The Journal of infection* 2020; **81**(2): 318-56.
- 24. Fang Z, Zhang Y, Hang C, Ai J, Li S, Zhang W. Comparisons of viral shedding time of SARS-CoV-2 of different samples in ICU and non-ICU patients. *The Journal of infection* 2020; **81**(1): 147-78.
- 25. Yilmaz A, Marklund E, Andersson M, et al. Upper Respiratory Tract Levels of Severe Acute
  Respiratory Syndrome Coronavirus 2 RNA and Duration of Viral RNA Shedding Do Not Differ

- Between Patients With Mild and Severe/Critical Coronavirus Disease 2019. *J Infect Dis* 2021; **223**(1): 15-8.
- 26. Gordon AC, Mouncey PR, Al-Beidh F, et al. Interleukin-6 Receptor Antagonists in Critically III

  Patients with Covid-19 Preliminary report. *medRxiv* 2021: 2021.01.07.21249390.
- 27. Simonovich VA, Burgos Pratx LD, Scibona P, et al. A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia. *N Engl J Med* 2020.
- 28. Haynes WA, Kamath K, Lucas C, Shon J, Iwasaki A. Impact of B.1.1.7 variant mutations on antibody recognition of linear SARS-CoV-2 epitopes. *medRxiv* 2021: 2021.01.06.20248960.
- 29. Hou YJ, Chiba S, Halfmann P, et al. SARS-CoV-2 D614G variant exhibits efficient replication ex vivo and transmission in vivo. *Science* 2020; **370**(6523): 1464-8.
- 30. Planas D, Bruel T, Grzelak L, et al. Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies. *bioRxiv* 2021: 2021.02.12.430472.

TABLE 1

SPECIFICITY AND SENSITVITY OF THE EIGHT POLYMORHISMS IN B.1.1.7 FOR STRAIN IDENTIFICATION

		H69/V70 deletion <sup>1</sup>		Y144 deletion		N501Y		A570D	
Strain	Source	WT	Del	WT	Del	Α	U	С	Α
B.1.1.7	$UK^2$	0	26,328	0	26,328	0	26,328	2	26,359
B.1.1.28	$AII^3$	374	0	374	0	294	80	374	0
B.1.351	$AII^4$	834	0	834	0	0	834	833	0
WT	$UK^4$	36,577	470	35,708	46	36,868	177	37,597	0
Specificity/Sensitivity <sup>5</sup>		98.73% / 100%		99.87% / 100%		99.52% / 100%		99.98% / 99.99%	

		P681H		T716I		S982A		D1118H	
Strain	Source	С	Α	С	U	U	G	G	С
B.1.1.7	UK	0	26,351	2	26,351	0	26,360	0	26,358
B.1.1.28	All	374	0	374	0	374	0	374	0
B.1.351	All	832	1	832	1	831	0	834	0
WT	UK	37,442	34	37,528	23	37,563	0	37,579	8
Specificity/Sensitivity		99.69% / 99.97%		99.94% / 99.99%		100% / 100%		99.98% / 99.97%	

<sup>&</sup>lt;sup>1</sup>For each mutation, mutations associated with B.1.1.7 shown in right hand column

<sup>&</sup>lt;sup>2</sup>Available sequences from GISAID Nov, Dec, 2020 and Jan, 2021


<sup>&</sup>lt;sup>3</sup>All available sequence worldwide

<sup>&</sup>lt;sup>4</sup>Available sequences from GISAID Jan-April, July, Nov, Dec, 2020 and Jan, 2021

<sup>&</sup>lt;sup>5</sup>Specificity and sensitivity for differentiation B.1.1.7 from WT SARS-CoV-2 sequences


## COMPARISON OF VIRAL LOADS IN ANTI-SARS-CoV-2 SEROPOSITIVE AND SERONEGATIVE SUBJECTS

FIGURE 1



(A) Viral loads of seropositive and seronegative study subjects determined by RT-qPCR of pre-treatment respiratory samples. Median values shown to the right of Tukey box plots. Distributions were compared by Kruskall-Wallis non-parametric test. (B) Frequency of seropositivity in individuals with different viral loads quantified in respiratory samples.

FIGURE 2
TEMPORAL EMERGENCE OF THE SARS-CoV-2 B.1.1.7 CLADE




Proportion of subjects with the B.1.1.7 clade virus enrolled to the REMAP-CAP trial in different weeks over the study period compared to proportions in the wider UK population from sequences deposited in GISAID. Numbers at the top of the graph indicate total enrolments / week.

FIGURE 3

REGIONAL REPRESENTATION OF STUDY SUBJECTS AND SARS-CoV-2 CASES WITH GENOTYPING DATA


AVAILABLE IN ENGLAND



Regional representation of subjects enrolled into the REMAP-CAP trial compared to distributions of SARS-CoV-2 infections proportions in England regions reported to PHE over the study period. Numbers at the top of the graph indicate enrolments numbers / region.

FIGURE 4

VIRAL LOAD OF WILD-TYPE AND B.1.1.7 STRAINS IN SEROPOSITIVE AND SEROGENATIVE SUBJECTS



Distributions of viral loads of in samples from patients infected with wild-type and B.1.1.7 strains, subdivided by serostatus. Distributions were compared by Kruskall-Wallis non-parametric test.